42.4% of adolescents with severe alopecia areata who received baricitinib had 80% or more scalp hair coverage after 36 weeks. An expert said it is the largest trial to date studying treatment in ...

Researchers examined the impact of baricitinib withdrawal and retreatment on hair regrowth in patients with severe alopecia areata. Although baricitinib has demonstrated efficacy for treating ...

Medically reviewed by Casey Gallagher, MD Alopecia areata is an autoimmune condition that causes abnormal inflammation around ...

1 "With these data, baricitinib is the most well-studied JAK inhibitor in severe alopecia areata, a chronic immune system disorder that can have an especially devastating social and emotional ...

These pathways have allowed health care providers to identify medicines that can work to treat alopecia areata. Olumiant contains the medicine baricitinib, which helps calm the overactive ...

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of the American Academy of Dermatology ...

How do you see the future of combination therapies, using baricitinib in conjunction with other treatments, for pediatric alopecia areata? As you know, in the real world, we don't have to do ...

There are three key oral JAK inhibitor players in alopecia areata: Eli Lilly’s Olumiant (baricitinib), Pfizer’s ritlecitinib, and Concert Pharmaceuticals’ CTP-543 (deuruxolitinib).

Alopecia universalis (AU) is a rare autoimmune condition that involves complete loss of hair on your face, scalp, and body.

If you haven’t found the right treatment for your alopecia areata yet, it may be right around the corner. There’s no cure for alopecia areata, but even with this condition, your hair follicles ...

The JAK1/2 inhibitor is the third oral JAK inhibitor approved for alopecia areata in the past 2 years, following baricitinib (Olumiant) and ritlecitinib (Litfulo), the latter of which has approval ...

with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes at Week 36.